Cyclooxygenase-2 in newborn hyperoxic lung injury

Rodney D Britt1, Markus Velten2, Trent E Tipple3

  • 1Center for Perinatal Research, The Research Institute at Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43205, USA.

Insights

Cyclooxygenase-2 (COX-2) inhibition reduced inflammation in newborn mice exposed to high oxygen, but did not prevent lung developmental deficits associated with bronchopulmonary dysplasia (BPD). This suggests COX-2 may be a therapeutic target for BPD-related inflammation.

Area of Science:

  • Neonatal physiology
  • Pulmonary medicine
  • Inflammation research

Background:

  • Bronchopulmonary dysplasia (BPD) is a chronic lung disease in preterm infants, often caused by supraphysiological oxygen concentrations and mechanical ventilation.
  • Hyperoxia exposure in newborn mice mimics BPD, leading to inflammation and impaired alveolarization.
  • Pulmonary cyclooxygenase-2 (COX-2) expression is elevated in hyperoxia-exposed newborn mice.

Purpose of the Study:

  • To investigate the role of COX-2 in hyperoxia-induced lung injury in newborn mice.
  • To test the hypothesis that inhibiting COX-2 activity would reduce inflammation and improve alveolarization.

Main Methods:

  • Newborn mice were treated with vehicle, aspirin, or celecoxib (COX-2 inhibitors) or used as wild-type, heterozygous, or homozygous COX-2 knockout models.
  • Mice were exposed to room air or 85% oxygen for 14 days.
  • Inflammatory markers, including monocyte chemoattractant protein-1 (MCP-1) and macrophage counts, were assessed in bronchoalveolar lavage fluid and lung tissue.

Main Results:

  • Aspirin and COX-2 knockout mice showed reduced MCP-1 levels in bronchoalveolar lavage fluid.
  • Aspirin and celecoxib treatments decreased macrophage infiltration and attenuated hyperoxia-induced COX activity.
  • Despite reduced inflammation, COX-2 inhibition did not prevent hyperoxia-induced lung developmental deficits.

Conclusions:

  • Increased COX-2 activity contributes to inflammatory responses, such as macrophage chemotaxis, during hyperoxia exposure.
  • Modulating COX-2 activity may be a potential therapeutic strategy to mitigate hyperoxia-induced inflammation in preterm infants at risk for BPD.
  • COX-2 inhibition alone does not fully prevent the lung structural damage associated with hyperoxia.

Related Concept Videos

Pneumothorax II: Pathophysiology01:08

Pneumothorax II: Pathophysiology

Pneumothorax means the presence of air in the pleural space — the thin potential gap between the visceral and parietal pleura. This condition disrupts the normal pressure balance that keeps the lungs inflated, leading to partial or complete collapse of the affected lung.Normal physiologyUnder normal conditions, the pleural space maintains a slightly negative intrapleural pressure, which keeps the lungs expanded against the chest wall. This negative pressure creates a delicate balance between...
Atelectasis II: Pathophysiology01:10

Atelectasis II: Pathophysiology

Atelectasis develops when alveoli lose their air and collapse inward. Because lung tissue is naturally elastic, these air sacs shrink rather than remaining open. Collapsed alveoli are no longer ventilated, reducing their role in gas exchange. Blood flow may continue in these regions, creating a ventilation–perfusion mismatch. Clinical findings include decreased breath sounds, dullness to percussion, reduced chest expansion, and decreased tactile fremitus as sound transmission through collapsed...
Oxygen Delivering System II: Venturi Mask and Transtracheal Oxygen01:16

Oxygen Delivering System II: Venturi Mask and Transtracheal Oxygen

Oxygen therapy is a pivotal aspect of medical care, particularly for patients with respiratory ailments. Two prominent oxygen-delivering systems include the Venturi mask and the transtracheal oxygen catheter.
Venturi Mask
The Venturi mask, named after the Venturi effect, is designed to deliver precise oxygen concentrations. It consists of a large tube with an oxygen inlet that narrows down, causing a pressure drop that pulls air in through adjustable side ports. The mask is a lightweight,...
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Oxygen Transport in the Blood01:27

Oxygen Transport in the Blood

Hemoglobin (Hb) is a crucial molecule in the human body, consisting of four polypeptide chains, each bound to an iron-containing heme group. This unique structure enables hemoglobin to bind to oxygen, with each molecule capable of combining with four molecules of oxygen, leading to rapid and reversible oxygen loading. When fully loaded with oxygen, it is called oxyhemoglobin, while hemoglobin that has released oxygen is called reduced hemoglobin or deoxyhemoglobin. As hemoglobin binds oxygen,...